New drug combo aims to shrink esophageal tumors before surgery
NCT ID NCT07263919
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the drug cadonilimab to standard chemotherapy before and after surgery helps people with a certain type of esophageal cancer. About 90 adults with resectable, locally advanced cancer will take part. The goal is to see if the combination leads to more complete tumor removal and better cancer control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE LOCALLY ADVANCED THORACIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Affiliated Hospital of Air Force Medical University
RECRUITINGXi'an, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.